Briefing

Industry news

Industry briefing

Covid-19 briefing

NEWS

FDA places full clinical hold on CytoDyn’s Covid-19 programme

BRIEFING

FDA issues new draft guidance to boost clinical trial diversity

Under the new guidance, medical product sponsors should submit a Race and Ethnicity Diversity Plan to the FDA

covid-19

Economic impact of Covid-19 continues to oscillate

After a strong post-Covid economic rebound recorded in 2021, the global growth is projected to decelerate markedly in 2022

Industry news

Industry briefing

Covid-19 briefing

02/24/2024 14:41:25
  • Home | Tackling insulin prices
  • In this issue
  • CSafe Global
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Briefing
  • Industry news
  • The pharma industry briefing
  • Covid-19 executive briefing by GlobalData
  • Molnar-Institute Company Insight
  • Molnar-Institute
  • Comment
  • Why did the cannabis industry blossom during the pandemic?
  • Negative AdCom vote for Amylyx’s ALS drug AMX0035, but hope remains
  • Will Russia’s invasion affect biopharmaceutical licensing agreements?
  • Fall from grace? What 2022 may have in stock for biopharmaceutical SPACs
  • BEA Technologies
  • In Depth
  • Insulin pricing: could an e-commerce approach cut costs?
  • Bacteria and balance: how understanding the vaginal microbiome can help discover new drugs
  • Big pharma’s gradual retreat on clinical trials in Russia
  • Covid-19, flu combo vaccines an advance but with rollout quandaries
  • FDA shows unease about marketing approval applications based on single-country t
  • In Data
  • How big is the gender pay gap in the pharma industry in Britain?
  • Where is trade most likely to be disrupted in pharma from the Russian invasion o
  • Big data innovation among pharma companies dropped off in the last quarter
  • Event: Outsourcing in Clinical Trials Europe 2022
  • Events
  • Next issue
04/26/2022 00:00:00